We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-10.34%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.95B
AUM Growth
-$1.05B
Cap. Flow
+$64.3M
Cap. Flow %
1.08%
Top 10 Hldgs %
34.22%
Holding
172
New
36
Increased
33
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$126M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$126M
3
PASG icon
Passage Bio
PASG
+$109M
4
PFE icon
Pfizer
PFE
+$108M
5
CNC icon
Centene
CNC
+$81M

Top Sells

Rank Stock Value
1
THOR
Synthorx, Inc. Common Stock
THOR
+$372M
2
ARQL
Arqule Inc
ARQL
+$99.8M
3
DHR icon
Danaher
DHR
+$98.1M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$79.2M
5
INSP icon
Inspire Medical Systems
INSP
+$74M

Sector Composition

Rank Sector Weight
1 Healthcare 96.88%
2 Financials 1.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
151
Insmed
INSM
$22.6B
– –
-59,000
Closed -$1.41M
IONS icon
152
Ionis Pharmaceuticals
IONS
$9.09B
– –
-106,900
Closed -$6.46M
KPTI icon
153
Karyopharm Therapeutics
KPTI
$155M
– –
-41,460
Closed -$11.9M
KRYS icon
154
Krystal Biotech
KRYS
$10.7B
– –
-994,808
Closed -$55.1M
MIST icon
155
Milestone Pharmaceuticals
MIST
$129M
– –
-364,206
Closed -$5.83M
MIRM icon
156
Mirum Pharmaceuticals
MIRM
$6.69B
– –
-71,300
Closed -$1.75M
PSNL icon
157
Personalis
PSNL
$1.24B
– –
-483,842
Closed -$5.27M
SNY icon
158
Sanofi
SNY
$109B
– –
-68,400
Closed -$3.43M
SPRO icon
159
Spero Therapeutics
SPRO
$67.7M
– –
-131,653
Closed -$1.27M
TNDM icon
160
Tandem Diabetes Care
TNDM
$1.24B
– –
-1,141,390
Closed -$68M
XBI icon
161
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.1B
– –
-110,000
Closed -$10.5M
ZBH icon
162
Zimmer Biomet
ZBH
$18.7B
– –
-184,061
Closed -$26.7M
XYLO
163
DELISTED
Xylo Technologies
XYLO
– –
-375
Closed -$26K
IMGN
164
DELISTED
Immunogen Inc
IMGN
– –
-286,800
Closed -$1.46M
ICPT
165
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-22,800
Closed -$2.83M
RUBY
166
PUT
DELISTED
Rubius Therapeutics, Inc
RUBY
– –
-100,000
Closed -$950K
MYOK
167
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-27,900
Closed -$2.03M
FOMX
168
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-2,577,982
Closed -$8.59M
DERM
169
CALL
DELISTED
Dermira, Inc.
DERM
– –
-250,000
Closed -$3.79M
THOR
170
DELISTED
Synthorx, Inc. Common Stock
THOR
– –
-5,316,355
Closed -$372M
ARQL
171
DELISTED
Arqule Inc
ARQL
– –
-5,000,000
Closed -$99.8M
ZGNX
172
CALL
DELISTED
Zogenix, Inc.
ZGNX
– –
-125,000
Closed -$6.52M
3 4 5 6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2020 Portfolio in Review

As of Q1 2020, OrbiMed held 172 positions worth $5.95B, down 15% from $7B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q1 2020 filing shows 36 new, 33 increased, 28 reduced and 30 closed positions. Its largest new stake was Arcutis Biotherapeutics: 4,673,850 shares worth $139M. The largest sale was Synthorx, Inc. Common Stock, an estimated $372M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q1 2020 buy was Arcutis Biotherapeutics: 4,673,850 shares worth $139M.
  • OrbiMed added most to Biogen in Q1 2020, an estimated $126M increase.
  • OrbiMed's biggest Q1 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $79.2M.
  • OrbiMed fully exited Synthorx, Inc. Common Stock in Q1 2020, selling an estimated $372M.
  • OrbiMed's ten largest holdings make up 34% of its $5.95B portfolio in Q1 2020.
  • OrbiMed opened 36 new positions and closed 30 in Q1 2020.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $5.95B.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.